



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

Date: January 19, 2022

Time: 10:00am – 3:00pm (CST)

Location: **REVISED – SEE BELOW**
See Additional Details Below

January 19, 2022 DUR Meeting Additional Details
The January 19th DUR meeting location has changed to the MO HealthNet building at
615 Howerton Ct Jefferson City, MO 65109, 2nd Floor Conference Room 202.
We will continue to have both in-person and virtual attendance options.

[Join Webex Meeting](#)

Meeting number (access code): 2464 144 0272
Meeting password: RfH4eQ9rpV4

Join from a Video System/Application
Dial [24641440272@stateofmo.webex.com](tel:24641440272)
Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions – New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	

Opioid Policy Review

11:00 – 11:45	<u>Opioid-Related Edits for Review</u>	Josh Moore
	i. High Risk Therapies Clinical Edit	
	ii. Morphine Milligram Equivalent (MME) Accumulation Clinical Edit	
	iii. Opioid Dependence Agents PDL Edit	
	iv. Opioid Emergency Reversal Agents PDL Edit	
	v. Opioids, Long Acting PDL Edit	
	vi. Opioids, Short Acting Clinical Edit	
	vii. Tramadol-Like Agents PDL Edit	
	viii. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit	

Clinical and Fiscal Edit Review

11:45 – 12:45

Existing Criteria

Josh Moore

- i. 15 Day Supply Oral Oncology Fiscal Edit
- ii. Butalbital Combinations without Codeine Clinical Edit
- iii. Butalbital Combinations Excessive Therapy Edit
- iv. Diabetic Supply Quantity Limit Fiscal Edit
- v. Out-of-State, Non-Bordering Pharmacies Fiscal Edit
- vi. Selzentry Clinical Edit

New Criteria or Revision of Existing Criteria

- i. 15 Day Supply Fiscal Edit
- ii. Acetaminophen Cumulative Dose Clinical Edit
- iii. Antipsychotics, 1st Generation (Typical) Clinical Edit
- iv. Antipsychotics, 2nd Generation (Atypical) Clinical Edit
- v. Benzodiazepine, Select Oral Clinical Edit
- vi. BiDil Clinical Edit
- vii. Biosimilar vs. Reference Products Fiscal Edit
- viii. Corlanor Clinical Edit
- ix. Empaveli Clinical Edit
- x. Extended Supply Fiscal Edit
- xi. High Cost Medications Fiscal Edit
- xii. Kerendia Clinical Edit
- xiii. Non-Oral Contraceptives Fiscal Edit
- xiv. Pompe Disease Clinical Edit
- xv. Spinal Muscular Atrophy (SMA) Clinical Edit

Break

12:45 – 1:00

Lunch

Preferred Drug List Edit Review

1:00 – 2:00

Existing Criteria

Josh Moore

- i. Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists
- ii. Anticonvulsants, Dravet Syndrome
- iii. Antiemetics, THC Derivatives
- iv. Anti-Parkinsonism, MAO-B Inhibitors
- v. Anti-Parkinsonism, Non-Ergot Dopamine Agonists
- vi. GI Motility Agents, Chronic
- vii. Somatostatin Analogs

New Criteria or Revision of Existing Criteria

- i. Antiandrogenic Agents
- ii. Antiemetics, 5-HT₃ and NK₁ Injectables
- iii. Antiemetics, 5-HT₃, NK₁ and Other Select Non-Injectables
- iv. Anti-Migraine, Alternative Oral Agents
- v. Anti-Migraine, Serotonin (5-HT₁) Receptor Agonists
- vi. Antiretroviral Therapy (ART)
- vii. Bile Salt Agents
- viii. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- ix. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors
- x. Fibromyalgia Agents
- xi. Glucagon Agents
- xii. Hereditary Angioedema Agents

- xiii. Homozygous Familial Hypercholesterolemia (HoFH)
- xiv. Neuropathic Pain Agents
- xv. NSAIDs
- xvi. Sedative Hypnotics
- xvii. Skeletal Muscle Relaxants
- xviii. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors

Program Utilization Information – Conduent Update

2:00 – 2:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

2:30 – 2:45 Other Business

Executive Session

2:45 – 3:00 Patient Profile Reviews

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

Next Meeting: April 20, 2022
Meeting location and attendance options subject to change

Howerton State Office Building 615 Howerton Ct Jefferson City, MO 65109 Conference Room 202 <i>Public attendance may be limited</i>		Webex
---	--	-------

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*